<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960607</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-059</org_study_id>
    <nct_id>NCT02960607</nct_id>
  </id_info>
  <brief_title>High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC</brief_title>
  <official_title>A Phase II Study of High-dose Icotinib in Previously Treated Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether high-dose icotinib treatment beyond&#xD;
      disease progression is beneficial for NSCLC patients who have EGFR mutation and who have&#xD;
      responded to EGFR TKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250mg, tid until disease progression or unacceptable toxicities occurred</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.</description>
    <arm_group_label>Icotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed stage IIIB/IV NSCLC&#xD;
&#xD;
          -  Investigator confirmed progression according RECIST 1.1 during previous icotinib&#xD;
             treatment&#xD;
&#xD;
          -  Patients whose tumors:&#xD;
&#xD;
               -  are EGFR mutation-positive or&#xD;
&#xD;
               -  T790M mutation-negative&#xD;
&#xD;
          -  Performance status: WHO 0-2&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
               -  at least one measureable lesion .if only one measureable lesion, the biological&#xD;
                  nature must be confirmed by cytology or histology&#xD;
&#xD;
               -  a single diameter of lesion could be measured by at least one of the following&#xD;
                  methods: Chest or abdominal computed tomography(CT)or magnetic resonance&#xD;
                  imaging(MRI),conventional methods of diameter at least 20mm diameter spiral CT OR&#xD;
                  at least 10mm&#xD;
&#xD;
          -  ANC ≥ 1.5*109/L, Platelets ≥ 75*109/L, Hgb≥ 9g/dL, Alanine amino transferase ≤ 2 ×&#xD;
             Upper limit of normal (ULN), Alkaline phosphatase ≤ 2.5 × ULN (&lt; 5 × ULN if liver&#xD;
             metastases), Serum Creatinine ≤ 1.5 × ULN&#xD;
&#xD;
          -  Women of childbearing age must have a pregnancy test 7 days before treatment and the&#xD;
             result were negative ,men of childbearing age: surgical sterilization or treatment&#xD;
             during and after the end of three months to take contraceptive measures&#xD;
&#xD;
          -  Patient must be able to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with symptomatic central nervous system metastases&#xD;
&#xD;
          -  Patient has known active hepatitis B or C, or HIV infection&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Patient with uncontrolled undercurrent illness or circumstances that could limit&#xD;
             compliance with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yutao Liu</last_name>
    <email>13911901165@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutao Liu, MD</last_name>
      <email>13911901165@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yutao Liu</investigator_full_name>
    <investigator_title>Associate Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

